MassDevice

Abbott reports strong outcomes for next-gen Amulet LAA occlusion device

Abbott today announced positive early results from a study evaluating its investigational Amulet 360 left atrial appendage ...
GlobalData on MSN

Abbott reports positive VERITAS study results for AFib

VERITAS involved 400 patients at 34 sites across Europe, Canada, and the US.

Cardiologist rethinks devices used to prevent stroke in patients with AFib

Approximately 10.5 million Americans have atrial fibrillation (AFib), a condition that causes an irregular, often too fast, ...
Medscape

Implantable Left Atrial Appendage Occluder Meets Early Primary Endpoints: VERITAS

The 45-day post-implantation results support use of a next-generation device in people with atrial fibrillation, but caution is advised until longer-term results are available.
MedTech Dive

4 takeaways from the 2026 AF Symposium

Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation ...
Pharmabiz

Abbott announces positive results from VERITAS study of Amulet 360 LAA Occluder, a next-generation implant designed to reduce risk of stroke in patients with AFib

Abbott Park, Illinois Monday, February 9, 2026, 13:00 Hrs [IST] ...
MassDevice

The biggest cardiac tech news out of the 2026 AF Symposium

Last week, the leading developers of treatments for atrial fibrillation (AFib) convened in Boston for the 2026 AF Symposium.
TCTMD

TCT 613: Intracardiac Echocardiography Compared to Transesophageal Echocardiography for Amulet Occluder Device for Left Atrial Appendage Closure

TCT 1285: Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): 5-year follow-up of a randomized controlled trial Receive the the latest news, research, and ...